The DOI matches its Crossref record; 154 of the 154 references it cites were found in a registry or an index.
Immunotherapy for glioma: Current management and future application
Open accessAbstract
Gliomas are intrinsic brain tumors that originate from neuroglial progenitor cells. Conventional therapies, including surgery, chemotherapy, and radiotherapy, have achieved limited improvements in the prognosis of glioma patients. Immunotherapy, a revolution in cancer treatment, has become a promising strategy with the ability to penetrate the blood-brain barrier since the pioneering discovery of lymphatics in the central nervous system. Here we detail the current management of gliomas and previous studies assessing different immunotherapies in gliomas, despite the fact that the associated clinical trials have not been completed yet. Moreover, several drugs that have undergone clinical trials are listed as novel strategies for future application; however, these clinical trials have indicated limited efficacy in glioma. Therefore, additional studies are warranted to evaluate novel therapeutic approaches in glioma treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary
Louis, D. N., Perry, A., Reifenberger, G., von Deimling, A., Figarella-Branger, D., Cavenee, W. K., Ohgaki, H., Wiestler, O. D., Kleihues, P., & Ellison, D. W. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1545-1 · Cited by 15,657
Ostrom, Q. T., Gittleman, H., Farah, P., Ondracek, A., Chen, Y., Wolinsky, Y., Stroup, N. E., Kruchko, C., & Barnholtz-Sloan, J. S. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not151 · Cited by 11,994
MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma
Hegi, M. E., Diserens, A.-C., Gorlia, T., Hamou, M.-F., de Tribolet, N., Weller, M., Kros, J. M., Hainfellner, J. A., Mason, W., Mariani, L., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043331 · Cited by 7,405
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., Redfern, C. H., Ferrari, A. C., Dreicer, R., Sims, R. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001294 · Cited by 5,572
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Wolchok, J. D., Chiarion-Sileni, V., Gonzalez, R., Rutkowski, P., Grob, J.-J., Cowey, C. L., Lao, C. D., Wagstaff, J., Schadendorf, D., Ferrucci, P. F., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709684 · Cited by 5,357
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J.-J., Rutkowski, P., Lao, C. D., Cowey, C. L., Schadendorf, D., Wagstaff, J., Dummer, R., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1910836 · Cited by 3,723
An immunogenic personal neoantigen vaccine for patients with melanoma
Ott, P. A., Hu, Z., Keskin, D. B., Shukla, S. A., Sun, J., Bozym, D. J., Zhang, W., Luoma, A., Giobbie-Hurder, A., Peter, L., et al. (2017) · Nature · doi:10.1038/nature22991 · Cited by 2,936
Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma
Andtbacka, R. H. I., Kaufman, H. L., Collichio, F., Amatruda, T., Senzer, N., Chesney, J., Delman, K. A., Spitler, L. E., Puzanov, I., Agarwala, S. S., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.3377 · Cited by 2,634
Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
Friedman, H. S., Prados, M. D., Wen, P. Y., Mikkelsen, T., Schiff, D., Abrey, L. E., Yung, W. K. A., Paleologos, N., Nicholas, M. K., Jensen, R., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.8721 · Cited by 2,466
CSF-1R inhibition alters macrophage polarization and blocks glioma progression
Pyonteck, S. M., Akkari, L., Schuhmacher, A. J., Bowman, R. L., Sevenich, L., Quail, D. F., Olson, O. C., Quick, M. L., Huse, J. T., Teijeiro, V., et al. (2013) · Nature Medicine · doi:10.1038/nm.3337 · Cited by 2,463
Tissue-resident macrophages originate from yolk-sac-derived erythro-myeloid progenitors
Gomez Perdiguero, E., Klapproth, K., Schulz, C., Busch, K., Azzoni, E., Crozet, L., Garner, H., Trouillet, C., de Bruijn, M. F., Geissmann, F., et al. (2015) · Nature · doi:10.1038/nature13989 · Cited by 2,339
The blood–brain barrier: an overview
Ballabh, P., Braun, A., & Nedergaard, M. (2004) · Neurobiology of Disease · doi:10.1016/j.nbd.2003.12.016 · Cited by 2,261
Ostrom, Q. T., Gittleman, H., Truitt, G., Boscia, A., Kruchko, C., & Barnholtz-Sloan, J. S. (2018) · Neuro-Oncology · doi:10.1093/neuonc/noy131 · Cited by 2,138
Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy
Brown, C. E., Alizadeh, D., Starr, R., Weng, L., Wagner, J. R., Naranjo, A., Ostberg, J. R., Blanchard, M. S., Kilpatrick, J., Simpson, J., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1610497 · Cited by 1,836
Robert, C., Ribas, A., Wolchok, J. D., Hodi, F. S., Hamid, O., Kefford, R., Weber, J. S., Joshua, A. M., Hwu, W.-J., Gangadhar, T. C., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60958-2 · Cited by 1,774
Self-citationAn Adenovirus Mutant That Replicates Selectively in p53- Deficient Human Tumor Cells
Bischoff, J. R., Kirn, D. H., Williams, A., Heise, C., Horn, S., Muna, M., Ng, L., Nye, J. A., Sampson-Johannes, A., Fattaey, A., et al. (1996) · Science · doi:10.1126/science.274.5286.373 · Cited by 1,760
Cytokines in cancer pathogenesis and cancer therapy
Dranoff, G. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1252 · Cited by 1,573
Cloughesy, T. F., Mochizuki, A. Y., Orpilla, J. R., Hugo, W., Lee, A. H., Davidson, T. B., Wang, A. C., Ellingson, B. M., Rytlewski, J. A., Sanders, C. M., et al. (2019) · Nature Medicine · doi:10.1038/s41591-018-0337-7 · Cited by 1,382
Ohgaki, H., & Kleihues, P. (2005) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/64.6.479 · Cited by 1,381
A new member of the immunoglobulin superfamily—CTLA-4
Brunet, J.-F., Denizot, F., Luciani, M.-F., Roux-Dosseto, M., Suzan, M., Mattei, M.-G., & Golstein, P. (1987) · Nature · doi:10.1038/328267a0 · Cited by 1,306
Stupp, R., Taillibert, S., Kanner, A. A., Kesari, S., Steinberg, D. M., Toms, S. A., Taylor, L. P., Lieberman, F., Silvani, A., Fink, K. L., et al. (2015) · JAMA · doi:10.1001/jama.2015.16669 · Cited by 1,259
Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial
Gilbert, M. R., Wang, M., Aldape, K. D., Stupp, R., Hegi, M. E., Jaeckle, K. A., Armstrong, T. S., Wefel, J. S., Won, M., Blumenthal, D. T., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.6968 · Cited by 1,063
Indoleamine 2,3 dioxygenase and metabolic control of immune responses
Munn, D. H., & Mellor, A. L. (2013) · Trends in Immunology · doi:10.1016/j.it.2012.10.001 · Cited by 1,037
Long, G. V., Dummer, R., Hamid, O., Gajewski, T. F., Caglevic, C., Dalle, S., Arance, A., Carlino, M. S., Grob, J.-J., Kim, T. M., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30274-8 · Cited by 960
CD28 and CTLA-4 coreceptor expression and signal transduction
Rudd, C. E., Taylor, A., & Schneider, H. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2009.00770.x · Cited by 898
Zeng, J., See, A. P., Phallen, J., Jackson, C. M., Belcaid, Z., Ruzevick, J., Durham, N., Meyer, C., Harris, T. J., Albesiano, E., et al. (2013) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2012.12.025 · Cited by 889
Ahmed, N., Brawley, V., Hegde, M., Bielamowicz, K., Kalra, M., Landi, D., Robertson, C., Gray, T. L., Diouf, O., Wakefield, A., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.0184 · Cited by 850
Disruption of cancer cell replication by alternating electric fields
Kirson, E. D., Gurvich, Z., Schneiderman, R., Dekel, E., Itzhaki, A., Wasserman, Y., Schatzberger, R., & Palti, Y. (2004) · Cancer research · doi:10.1158/0008-5472.can-04-0083 · Cited by 827
Recurrent Glioblastoma Treated with Recombinant Poliovirus
Desjardins, A., Gromeier, M., Herndon, J. E., Beaubier, N., Bolognesi, D. P., Friedman, A. H., Friedman, H. S., McSherry, F., Muscat, A. M., Nair, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716435 · Cited by 815
Brown, C. E., Badie, B., Barish, M. E., Weng, L., Ostberg, J. R., Chang, W.-C., Naranjo, A., Starr, R., Wagner, J., Wright, C., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0428 · Cited by 764
Rupp, L. J., Schumann, K., Roybal, K. T., Gate, R. E., Ye, C. J., Lim, W. A., & Marson, A. (2017) · Scientific Reports · doi:10.1038/s41598-017-00462-8 · Cited by 757
Lang, F. F., Conrad, C., Gomez-Manzano, C., Yung, W. K. A., Sawaya, R., Weinberg, J. S., Prabhu, S. S., Rao, G., Fuller, G. N., Aldape, K. D., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.8219 · Cited by 711
Majzner, R. G., Theruvath, J. L., Nellan, A., Heitzeneder, S., Cui, Y., Mount, C. W., Rietberg, S. P., Linde, M. H., Xu, P., Rota, C., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0432 · Cited by 681
Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape
Hegde, M., Mukherjee, M., Grada, Z., Pignata, A., Landi, D., Navai, S. A., Wakefield, A., Fousek, K., Bielamowicz, K., Chow, K. K. H., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci83416 · Cited by 677
The tumor microenvironment underlies acquired resistance to CSF-1R inhibition in gliomas
Quail, D. F., Bowman, R. L., Akkari, L., Quick, M. L., Schuhmacher, A. J., Huse, J. T., Holland, E. C., Sutton, J. C., & Joyce, J. A. (2016) · Science · doi:10.1126/science.aad3018 · Cited by 666
FDA Drug Approval Summary: Bevacizumab (Avastin®) as Treatment of Recurrent Glioblastoma Multiforme
Cohen, M. H., Shen, Y. L., Keegan, P., & Pazdur, R. (2009) · The Oncologist · doi:10.1634/theoncologist.2009-0121 · Cited by 655
Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma
Schalper, K. A., Rodriguez-Ruiz, M. E., Diez-Valle, R., López-Janeiro, A., Porciuncula, A., Idoate, M. A., Inogés, S., de Andrea, C., López-Diaz de Cerio, A., Tejada, S., et al. (2019) · Nature Medicine · doi:10.1038/s41591-018-0339-5 · Cited by 642
Alternative molecular formats and therapeutic applications for bispecific antibodies
Spiess, C., Zhai, Q., & Carter, P. J. (2015) · Molecular Immunology · doi:10.1016/j.molimm.2015.01.003 · Cited by 607
Butowski, N., Colman, H., De Groot, J. F., Omuro, A. M., Nayak, L., Wen, P. Y., Cloughesy, T. F., Marimuthu, A., Haidar, S., Perry, A., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/nov245 · Cited by 593
Oncolytic Viruses in Cancer Treatment: A Review
Lawler, S. E., Speranza, M.-C., Cho, C.-F., & Chiocca, E. A. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2016.2064 · Cited by 592
Wainwright, D. A., Chang, A. L., Dey, M., Balyasnikova, I. V., Kim, C. K., Tobias, A., Cheng, Y., Kim, J. W., Qiao, J., Zhang, L., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0514 · Cited by 576
Okada, H., Kalinski, P., Ueda, R., Hoji, A., Kohanbash, G., Donegan, T. E., Mintz, A. H., Engh, J. A., Bartlett, D. L., Brown, C. K., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.7744 · Cited by 567
Yu, J. S., Wheeler, C. J., Zeltzer, P. M., Ying, H., Nacis-Finger, D., Lee, P.-K., Yong, W. H., Incardona, F., Thompson, R. C., Riedinger, M. S., et al. (2001) · PubMed · Cited by 510
Design and development of therapies using chimeric antigen receptor‐expressing T cells
Dotti, G., Gottschalk, S., Savoldo, B., & Brenner, M. K. (2014) · Immunological Reviews · doi:10.1111/imr.12131 · Cited by 508
Nivolumab Monotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer
Gettinger, S., Rizvi, N. A., Chow, L. Q., Borghaei, H., Brahmer, J., Ready, N., Gerber, D. E., Shepherd, F. A., Antonia, S., Goldman, J. W., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.66.9929 · Cited by 501
China Approves World's First Oncolytic Virus Therapy For Cancer Treatment
Garber, K. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj111 · Cited by 489
Omuro, A., Vlahovic, G., Lim, M., Sahebjam, S., Baehring, J., Cloughesy, T., Voloschin, A., Ramkissoon, S. H., Ligon, K. L., Latek, R., et al. (2018) · Neuro-Oncology · doi:10.1093/neuonc/nox208 · Cited by 486
Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma
Kunwar, S., Chang, S., Westphal, M., Vogelbaum, M., Sampson, J., Barnett, G., Shaffrey, M., Ram, Z., Piepmeier, J., Prados, M., et al. (2010) · Neuro-Oncology · doi:10.1093/neuonc/nop054 · Cited by 483
Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer
Prendergast, G. C., Smith, C., Thomas, S., Mandik-Nayak, L., Laury-Kleintop, L., Metz, R., & Muller, A. J. (2014) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-014-1549-4 · Cited by 482
Ye, X.-Z., Xu, S.-L., Xin, Y.-H., Yu, S.-C., Ping, Y.-F., Chen, L., Xiao, H.-L., Wang, B., Yi, L., Wang, Q.-L., et al. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1103248 · Cited by 477
Self-citationWainwright, D. A., Balyasnikova, I. V., Chang, A. L., Ahmed, A. U., Moon, K.-S., Auffinger, B., Tobias, A. L., Han, Y., & Lesniak, M. S. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2130 · Cited by 472
Bloch, O., Crane, C. A., Kaur, R., Safaee, M., Rutkowski, M. J., & Parsa, A. T. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3314 · Cited by 458
Recent advances in the molecular understanding of glioblastoma
Bleeker, F. E., Molenaar, R. J., & Leenstra, S. (2012) · Journal of Neuro-Oncology · doi:10.1007/s11060-011-0793-0 · Cited by 456
Zhang, L., Morgan, R. A., Beane, J. D., Zheng, Z., Dudley, M. E., Kassim, S. H., Nahvi, A. V., Ngo, L. T., Sherry, R. M., Phan, G. Q., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2085 · Cited by 444
Chiocca, E. A., Abbed, K. M., Tatter, S., Louis, D. N., Hochberg, F. H., Barker, F., Kracher, J., Grossman, S. A., Fisher, J. D., Carson, K., et al. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2004.07.021 · Cited by 436
Coniglio, S. J., Eugenin, E., Dobrenis, K., Stanley, E. R., West, B. L., Symons, M. H., & Segall, J. E. (2012) · Molecular Medicine · doi:10.2119/molmed.2011.00217 · Cited by 428
Regulatory T-cell inhibition versus depletion: the right choice in cancer immunotherapy
Colombo, M. P., & Piconese, S. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2250 · Cited by 407
Reardon, D. A., Gokhale, P. C., Klein, S. R., Ligon, K. L., Rodig, S. J., Ramkissoon, S. H., Jones, K. L., Conway, A. S., Liao, X., Zhou, J., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0151 · Cited by 405
Phuphanich, S., Wheeler, C. J., Rudnick, J. D., Mazer, M., Wang, H., Nuño, M. A., Richardson, J. E., Fan, X., Ji, J., Chu, R. M., et al. (2013) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-012-1319-0 · Cited by 388
Ahmed, N., Salsman, V. S., Kew, Y., Shaffer, D., Powell, S., Zhang, Y. J., Grossman, R. G., Heslop, H. E., & Gottschalk, S. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1322 · Cited by 384
Kloepper, J., Riedemann, L., Amoozgar, Z., Seano, G., Susek, K., Yu, V., Dalvie, N., Amelung, R. L., Datta, M., Song, J. W., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1525360113 · Cited by 357
Fecci, P. E., Ochiai, H., Mitchell, D. A., Grossi, P. M., Sweeney, A. E., Archer, G. E., Cummings, T., Allison, J. P., Bigner, D. D., & Sampson, J. H. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2070 · Cited by 347
Kunwar, S., Prados, M. D., Chang, S. M., Berger, M. S., Lang, F. F., Piepmeier, J. M., Sampson, J. H., Ram, Z., Gutin, P. H., Gibbons, R. D., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.1117 · Cited by 325
T cell receptor‐based cancer immunotherapy: Emerging efficacy and pathways of resistance
Chandran, S. S., & Klebanoff, C. A. (2019) · Immunological Reviews · doi:10.1111/imr.12772 · Cited by 323
Markert, J. M., Razdan, S. N., Kuo, H.-C., Cantor, A., Knoll, A., Karrasch, M., Nabors, L. B., Markiewicz, M., Agee, B. S., Coleman, J. M., et al. (2014) · Molecular Therapy · doi:10.1038/mt.2014.22 · Cited by 319
Vik-Mo, E. O., Nyakas, M., Mikkelsen, B. V., Moe, M. C., Due-Tønnesen, P., Suso, E. M. I., Sæbøe-Larssen, S., Sandberg, C., Brinchmann, J. E., Helseth, E., et al. (2013) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-013-1453-3 · Cited by 315
CAR T-cell therapy for glioblastoma: recent clinical advances and future challenges
Bagley, S. J., Desai, A. S., Linette, G. P., June, C. H., & O’Rourke, D. M. (2018) · Neuro-Oncology · doi:10.1093/neuonc/noy032 · Cited by 312
Morgan, R. A., Johnson, L. A., Davis, J. L., Zheng, Z., Woolard, K. D., Reap, E. A., Feldman, S. A., Chinnasamy, N., Kuan, C.-T., Song, H., et al. (2012) · Human Gene Therapy · doi:10.1089/hum.2012.041 · Cited by 311
Brown, C. E., Aguilar, B., Starr, R., Yang, X., Chang, W.-C., Weng, L., Chang, B., Sarkissian, A., Brito, A., Sanchez, J. F., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2017.10.002 · Cited by 299
Vaccination Elicits Correlated Immune and Clinical Responses in Glioblastoma Multiforme Patients
Wheeler, C. J., Black, K. L., Liu, G., Mazer, M., Zhang, X.-X., Pepkowitz, S., Goldfinger, D., Ng, H., Irvin, D., & Yu, J. S. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5973 · Cited by 296
Long-term Survival in Glioblastoma with Cytomegalovirus pp65-Targeted Vaccination
Batich, K. A., Reap, E. A., Archer, G. E., Sanchez-Perez, L., Nair, S. K., Schmittling, R. J., Norberg, P., Xie, W., Herndon, J. E., Healy, P., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2057 · Cited by 295
Sampson, J. H., Choi, B. D., Sanchez-Perez, L., Suryadevara, C. M., Snyder, D. J., Flores, C. T., Schmittling, R. J., Nair, S. K., Reap, E. A., Norberg, P. K., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0709 · Cited by 291
Sampson, J. H., Archer, G. E., Mitchell, D. A., Heimberger, A. B., Herndon, J. E., Lally-Goss, D., McGehee-Norman, S., Paolino, A., Reardon, D. A., Friedman, A. H., et al. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0124 · Cited by 287
Wen, P. Y., Reardon, D. A., Armstrong, T. S., Phuphanich, S., Aiken, R. D., Landolfi, J. C., Curry, W. T., Zhu, J.-J., Glantz, M., Peereboom, D. M., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0261 · Cited by 287
Long, G. V., Weber, J. S., Infante, J. R., Kim, K. B., Daud, A., Gonzalez, R., Sosman, J. A., Hamid, O., Schuchter, L., Cebon, J., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.9345 · Cited by 285
Oberoi, R. K., Parrish, K. E., Sio, T. T., Mittapalli, R. K., Elmquist, W. F., & Sarkaria, J. N. (2016) · Neuro-Oncology · doi:10.1093/neuonc/nov164 · Cited by 280
Flow Cytometric Characterization of Tumor-associated Macrophages in Experimental Gliomas
Badie, B., & Schartner, J. M. (2000) · Neurosurgery · doi:10.1097/00006123-200004000-00035 · Cited by 278
Yasuda, S., Sho, M., Yamato, I., Yoshiji, H., Wakatsuki, K., Nishiwada, S., Yagita, H., & Nakajima, Y. (2013) · Clinical and Experimental Immunology · doi:10.1111/cei.12069 · Cited by 276
De Vleeschouwer, S., Fieuws, S., Rutkowski, S., Van Calenbergh, F., Van Loon, J., Goffin, J., Sciot, R., Wilms, G., Demaerel, P., Warmuth-Metz, M., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4875 · Cited by 271
Kikuchi, T., Akasaki, Y., Irie, M., Homma, S., Abe, T., & Ohno, T. (2001) · Cancer Immunology, Immunotherapy · doi:10.1007/s002620100205 · Cited by 270
Wesolowska, A., Kwiatkowska, A., Slomnicki, L., Dembinski, M., Master, A., Sliwa, M., Franciszkiewicz, K., Chouaib, S., & Kaminska, B. (2008) · Oncogene · doi:10.1038/sj.onc.1210683 · Cited by 258
Gabrusiewicz, K., Ellert-Miklaszewska, A., Lipko, M., Sielska, M., Frankowska, M., & Kaminska, B. (2011) · PLoS ONE · doi:10.1371/journal.pone.0023902 · Cited by 257
Belcaid, Z., Phallen, J. A., Zeng, J., See, A. P., Mathios, D., Gottschalk, C., Nicholas, S., Kellett, M., Ruzevick, J., Jackson, C., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0101764 · Cited by 244
Interferon-gamma in the first-line therapy of ovarian cancer: a randomized phase III trial
Windbichler, G. H., Hausmaninger, H., Stummvoll, W., Graf, A. H., Kainz, C., Lahodny, J., Denison, U., Müller-Holzner, E., & Marth, C. (2000) · British Journal of Cancer · doi:10.1054/bjoc.1999.1053 · Cited by 241
NCCN Guidelines Insights: Central Nervous System Cancers, Version 1.2017
Nabors, L. B., Portnow, J., Ammirati, M., Baehring, J., Brem, H., Butowski, N., Fenstermaker, R. A., Forsyth, P., Hattangadi-Gluth, J., Holdhoff, M., et al. (2017) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2017.0166 · Cited by 231
Intratumoral IL-12 combined with CTLA-4 blockade elicits T cell–mediated glioma rejection
vom Berg, J., Vrohlings, M., Haller, S., Haimovici, A., Kulig, P., Sledzinska, A., Weller, M., & Becher, B. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20130678 · Cited by 213
Grauer, O. M., Nierkens, S., Bennink, E., Toonen, L. W. J., Boon, L., Wesseling, P., Sutmuller, R. P. M., & Adema, G. J. (2007) · International Journal of Cancer · doi:10.1002/ijc.22607 · Cited by 212
CD70, a novel target of CAR T-cell therapy for gliomas
Jin, L., Ge, H., Long, Y., Yang, C., Chang, Y. (., Mu, L., Sayour, E. J., De Leon, G., Wang, Q. J., Yang, J. C., et al. (2018) · Neuro-Oncology · doi:10.1093/neuonc/nox116 · Cited by 211
Weber, F., Asher, A., Bucholz, R., Berger, M., Prados, M., Chang, S., Bruce, J., Hall, W., Rainov, N. G., Westphal, M., et al. (2003) · Journal of Neuro-oncology · doi:10.1007/bf02700027 · Cited by 205
B7-H3 as a Novel CAR-T Therapeutic Target for Glioblastoma
Tang, X., Zhao, S., Zhang, Y., Wang, Y., Zhang, Z., Yang, M., Zhu, Y., Zhang, G., Guo, G., Tong, A., et al. (2019) · Molecular Therapy - Oncolytics · doi:10.1016/j.omto.2019.07.002 · Cited by 197
Zhang, J., Sarkar, S., Cua, R., Zhou, Y., Hader, W., & Yong, V. W. (2012) · Carcinogenesis · doi:10.1093/carcin/bgr289 · Cited by 196
Genoud, V., Marinari, E., Nikolaev, S. I., Castle, J. C., Bukur, V., Dietrich, P.-Y., Okada, H., & Walker, P. R. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1501137 · Cited by 193
Systemic delivery of neutralizing antibody targeting CCL2 for glioma therapy
Zhu, X., Fujita, M., Snyder, L. A., & Okada, H. (2011) · Journal of Neuro-Oncology · doi:10.1007/s11060-010-0473-5 · Cited by 189
Lamfers, M. L. M., Grill, J., Dirven, C. M. F., van Beusechem, V. W., Geoerger, B., Berg, J. V. D., Alemany, R., Fueyo-Margareto, J., Curiel, D. T., Vassal, G., et al. (2002) · PubMed · Cited by 183
B7-H3-redirected chimeric antigen receptor T cells target glioblastoma and neurospheres
Nehama, D., Di Ianni, N., Musio, S., Du, H., Patané, M., Pollo, B., Finocchiaro, G., Park, J. J. H., Dunn, D. E., Edwards, D. S., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.08.030 · Cited by 183
Molenaar, R. J., Radivoyevitch, T., Maciejewski, J. P., van Noorden, C. J. F., & Bleeker, F. E. (2014) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2014.05.004 · Cited by 182
Köhnke, T., Krupka, C., Tischer, J., Knösel, T., & Subklewe, M. (2015) · Journal of Hematology & Oncology · doi:10.1186/s13045-015-0213-6 · Cited by 174
Cho, D.-Y., Yang, W.-K., Lee, H.-C., Hsu, D.-M., Lin, H.-L., Lin, S.-Z., Chen, C.-C., Harn, H.-J., Liu, C.-L., Lee, W.-Y., et al. (2012) · World Neurosurgery · doi:10.1016/j.wneu.2011.08.020 · Cited by 166
Ardon, H., Van Gool, S. W., Verschuere, T., Maes, W., Fieuws, S., Sciot, R., Wilms, G., Demaerel, P., Goffin, J., Van Calenbergh, F., et al. (2012) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-012-1261-1 · Cited by 165
Kaminska, B., Mota, M., & Pizzi, M. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2015.10.026 · Cited by 162
RAGE Expression in Tumor-Associated Macrophages Promotes Angiogenesis in Glioma
Chen, X., Zhang, L., Zhang, I. Y., Liang, J., Wang, H., Ouyang, M., Wu, S., da Fonseca, A. C. C., Weng, L., Yamamoto, Y., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-1240 · Cited by 156
Natsume, A., Ishii, D., Wakabayashi, T., Tsuno, T., Hatano, H., Mizuno, M., & Yoshida, J. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0036 · Cited by 156
Chang, C.-N., Huang, Y.-C., Yang, D.-M., Kikuta, K., Wei, K.-J., Kubota, T., & Yang, W.-K. (2011) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2010.11.034 · Cited by 151
Microglial/macrophage expression of interleukin 10 in human glioblastomas
Wagner, S., Czub, S., Greif, M., Vince, G. H., S�ss, N., Kerkau, S., Rieckmann, P., Roggendorf, W., Roosen, K., & Tonn, J. C. (1999) · International Journal of Cancer · Cited by 149
Ardon, H., Gool, S. V., Lopes, I. S., Maes, W., Sciot, R., Wilms, G., Demaerel, P., Bijttebier, P., Claes, L., Goffin, J., et al. (2010) · Journal of Neuro-Oncology · doi:10.1007/s11060-010-0131-y · Cited by 147
Adjuvant dendritic cell‐based tumour vaccination for children with malignant brain tumours
Ardon, H., Vleeschouwer, S. D., Calenbergh, F. V., Claes, L., Kramm, C. M., Rutkowski, S., Wolff, J. E. A., & Gool, S. W. V. (2009) · Pediatric Blood & Cancer · doi:10.1002/pbc.22319 · Cited by 144
Li, M., Bolduc, A. R., Hoda, M. N., Gamble, D. N., Dolisca, S.-B., Bolduc, A., Hoang, K., Ashley, C., McCall, D. C., Rojiani, A. M., et al. (2014) · Journal for ImmunoTherapy of Cancer · doi:10.1186/2051-1426-2-21 · Cited by 144
Inogés, S., Tejada, S., de Cerio, A. L.-D., Pérez‐Larraya, J. G., Espinós, J., Idoate, M. A., Domínguez, P. D., de Eulate, M. R. G., Aristu, J., Bendandi, M., et al. (2017) · Journal of Translational Medicine · doi:10.1186/s12967-017-1202-z · Cited by 143
TGF Beta Signaling and Its Role in Glioma Pathogenesis
Kaminska, B., Kocyk, M., & Kijewska, M. (2012) · Advances in experimental medicine and biology · doi:10.1007/978-94-007-4719-7_9 · Cited by 141
Choi, B. D., Kuan, C., Cai, M., Archer, G. E., Mitchell, D. A., Gedeon, P. C., Sanchez-Perez, L. A., Pastan, I. H., Bigner, D. D., & Sampson, J. H. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1219817110 · Cited by 137
Limitations and Off-Target Effects of Tryptophan-Related IDO Inhibitors in Cancer Treatment
Günther, J., Däbritz, J., & Wirthgen, E. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01801 · Cited by 137
Okada, H., Lieberman, F. S., Walter, K. A., Lunsford, L. D., Kondziolka, D. S., Bejjani, G. K., Hamilton, R. L., Torres-Trejo, A., Kaliński, P., Cai, Q., et al. (2007) · Journal of Translational Medicine · doi:10.1186/1479-5876-5-67 · Cited by 130
Colombo, F., Barzon, L., Franchin, E., Pacenti, M., Pinna, V., Danieli, D., Zanusso, M., & Palù, G. (2005) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700851 · Cited by 129
Prins, R. M., Wang, X., Soto, H., Young, E., Lisiero, D. N., Fong, B., Everson, R. G., Yong, W. H., Lai, A., Li, G., et al. (2013) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3182811ae4 · Cited by 120
Hu, F., Ku, M., Markovic, D. S., Dzaye, O. D. A., Lehnardt, S., Synowitz, M., Wolf, S. A., & Kettenmann, H. (2014) · International Journal of Cancer · doi:10.1002/ijc.28908 · Cited by 119
Fong, B., Jin, R. M., Wang, X., Safaee, M., Lisiero, D. N., Yang, I., Li, G., Liau, L. M., & Prins, R. M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0032614 · Cited by 108
The PD-1/B7-H1 Pathway Modulates the Natural Killer Cells versus Mouse Glioma Stem Cells
Huang, B. Y., Zhan, Y. P., Zong, W. J., Yu, C. J., Li, J., Qu, Y. M., & Han, S. (2015) · PLoS ONE · doi:10.1371/journal.pone.0134715 · Cited by 108
Interferon Lambda: A New Sword in Cancer Immunotherapy
Lasfar, A., Abushahba, W., Balan, M., & Cohen-Solal, K. (2011) · Clinical and Developmental Immunology · doi:10.1155/2011/349575 · Cited by 102
Shen, C.-J., Yang, Y.-X., Han, E. Q., Cao, N., Wang, Y.-F., Wang, Y., Zhao, Y.-Y., Zhao, L.-M., Cui, J., Gupta, P. K., et al. (2013) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-6-33 · Cited by 100
Pembrolizumab and nivolumab: PD-1 inhibitors for advanced melanoma
Ivashko, I. N., & Kolesar, J. (2016) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp140768 · Cited by 95
Initiative action of tumor-associated macrophage during tumor metastasis
Singh, S., Mehta, N., Lilan, J., Budhthoki, M. B., Fu, C., & Li, Y. (2017) · Biochimie Open · doi:10.1016/j.biopen.2016.11.002 · Cited by 87
Hanihara, M., Kawataki, T., Oh‐oka, K., Mitsuka, K., Nakao, A., & Kinouchi, H. (2015) · Journal of neurosurgery · doi:10.3171/2015.5.jns141901 · Cited by 85
Chimeric antigen receptors: driving immunology towards synthetic biology
Sadelain, M. (2016) · Current Opinion in Immunology · doi:10.1016/j.coi.2016.06.004 · Cited by 85
Yu, C., Fu, S., Chen, X., Ye, J., Yuan, Y., Kong, L.-D., & Zhu, Z. (2018) · Cellular Physiology and Biochemistry · doi:10.1159/000492849 · Cited by 81
Alessandrini, F., Menotti, L., Avitabile, E., Appolloni, I., Ceresa, D., Marubbi, D., Campadelli‐Fiume, G., & Malatesta, P. (2019) · Oncogene · doi:10.1038/s41388-019-0737-2 · Cited by 79
Wakabayashi, T., Natsume, A., Hashizume, Y., Fujii, M., Mizuno, M., & Yoshida, J. (2008) · The Journal of Gene Medicine · doi:10.1002/jgm.1160 · Cited by 76
Giannopoulos, A., Constantinides, C. A., Fokaeas, E., Stravodimos, C., Giannopoulou, M., Kyroudi, A., & Gounaris, A. (2003) · PubMed · Cited by 75
Mieczkowski, J., Kocyk, M., Nauman, P., Gabrusiewicz, K. R., Sielska, M., Przanowski, P., Maleszewska, M., Rajan, W. D., Pszczolkowska, D., Tykocki, T., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5310 · Cited by 72
Learn, C. A., Fecci, P. E., Schmittling, R. J., Xie, W., Karikari, I. O., Mitchell, D. A., Archer, G. E., Wei, Z., Dressman, H. K., & Sampson, J. H. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1727 · Cited by 71
Caratelli, S., Sconocchia, T., Arriga, R., Coppola, A., Lanzilli, G., Lauro, D., Venditti, A., Principe, M. I. D., Buccisano, F., Maurillo, L., et al. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00457 · Cited by 71
Färkkilä, M. A., Jääskeläinen, J. E., Kallio, M., Blomstedt, G. C., Raininko, R., Virkkunen, P. J., Paetau, A. E., SARELIN, H., & Mäntylä, M. (1994) · British Journal of Cancer · doi:10.1038/bjc.1994.263 · Cited by 70
Holladay, F. P., Heitz, T., Bayer, W. L., & Wood, G. W. (1996) · Journal of Neuro-Oncology · doi:10.1007/bf00177482 · Cited by 66
Morris, C. S., & Esiri, M. M. (1991) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(91)90017-2 · Cited by 65
Jacobs, V. L., Landry, R. P., Liu, Y., Romero-Sandoval, E. A., & Leo, J. A. D. (2011) · Neuro-Oncology · doi:10.1093/neuonc/nor194 · Cited by 63
Natsume, A., Wakabayashi, T., Ishii, D., Maruta, H., Fujii, M., Shimato, S., Ito, M., & Yoshida, J. (2007) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-007-0520-x · Cited by 62
Baral, A., YE, H. X., JIANG, P. C., Yao, Y., & Mao, Y. Q. (2014) · Oncology Letters · doi:10.3892/ol.2014.2268 · Cited by 61
Gedeon, P. C., Schaller, T. H., Chitneni, S. K., Choi, B. D., Kuan, C., Suryadevara, C. M., Snyder, D. J., Schmittling, R. J., Szafranski, S. E., Cui, X., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0126 · Cited by 58
Dendritic cell vaccines for high-grade gliomas
Eagles, M. E., Nassiri, F., Badhiwala, J. H., Suppiah, S., Almenawer, S. A., Zadeh, G. M., & Aldape, K. (2018) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s135865 · Cited by 57
Groves, M. D., Puduvalli, V. K., GILBERT, M. R., Levin, V. A., Conrad, C. A., Liu, V., Hunter, K., Meyers, C., Hess, K. R., & Yung, W. K. A. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605189 · Cited by 50
Immune genes are associated with human glioblastoma pathology and patient survival
Vauléon, É., Avril, T., Hamlat, A., Etcheverry, A., Chiforeanu, D. C., Meneï, P., Mosser, J., Quillien, V., & Aubry, M. (2012) · BMC Medical Genomics · doi:10.1186/1755-8794-5-41 · Cited by 50
Huang, B., Luo, L., Wang, J., He, B., Feng, R., Xian, N., Zhang, Q., Chen, L., & Huang, G. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1684127 · Cited by 50
Coventry, B. J., & Ashdown (2012) · Cancer Management and Research · doi:10.2147/cmar.s33979 · Cited by 47
Advances and challenges: dendritic cell vaccination strategies for glioblastoma
Schaller, T. H., & Sampson, J. H. (2016) · Expert Review of Vaccines · doi:10.1080/14760584.2016.1218762 · Cited by 45
Jahan, N., Talat, H., Alonso, A., Saha, D., & Curry, W. T. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1577108 · Cited by 45
Wang, Z., Bao, Z., Yan, W., You, G., Wang, Y., Li, X., & Zhang, W. (2013) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-32-59 · Cited by 44
Self-citationThe 2018 Nobel Prize in Physiology or Medicine: An exemplar of bench to bedside in immunology
Ballas, Z. K. (2018) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2018.10.021 · Cited by 44
Parney, I. F., Chang, L.-J., Farr-Jones, M. A., Hao, C., Smylie, M., & Petruk, K. C. (2006) · Journal of Neuro-Oncology · doi:10.1007/s11060-005-9058-0 · Cited by 42
Zhang, L., Tai, Y., Ho, M., Qiu, L., & Anderson, K. C. (2017) · Experimental Hematology and Oncology · doi:10.1186/s40164-017-0081-6 · Cited by 42
Chen, L., YUAN, W., Chen, Z., Wu, S., Ge, J., Chen, J., & Chen, Z. (2015) · International Journal of Oncology · doi:10.3892/ijo.2015.3126 · Cited by 31
Sun, S., Du, G., Xue, J., Ma, J., Ge, M., Wang, H., & Tian, J. (2018) · International Journal of Immunopathology and Pharmacology · doi:10.1177/2058738418787991 · Cited by 25
Marei, H. E. S., Al-Thani, A., Caceci, T., Arriga, R., Sconocchia, T., Ottaviani, A., Lanzilli, G., Roselli, M., Caratelli, S., Cenciarelli, C., et al. (2019) · Biochemical Pharmacology · doi:10.1016/j.bcp.2019.06.002 · Cited by 25
Amin, A., Plimack, E. R., Infante, J. R., Ernstoff, M. S., Rini, B. I., McDermott, D. F., Knox, J. J., Pal, S. K., Voss, M. H., Sharma, P., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu342.5 · Cited by 23
Fong, B., Jin, R. M., Wang, X., Safaee, M., Lisiero, D. N., Yang, I., Li, G., Liau, L. M., & Prins, R. M. (2012) · PLoS ONE · doi:10.1371/annotation/641c3e73-ee2c-4873-8896-1b3a2edc557b · Cited by 13
Cited by
Liu, S., Liu, J., Li, H., Mao, K., Wang, H., Meng, X., Wang, J., Wu, C., Chen, H., Wang, X., et al. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121645 · Cited by 122
Role of the tumor microenvironment in cancer hallmarks and targeted therapy (Review)
Naser, R., Fakhoury, I., El‑Fouani, A., Abi‑Habib, R., & El‑Sibai, M. (2022) · International Journal of Oncology · doi:10.3892/ijo.2022.5471 · Cited by 61
Metadata
- Authors
- Xu, S., Tang, L., Li, X., Fan, F., & Liu, Z.
- Venue
- Cancer Letters
- Publisher
- Elsevier BV
- Published
- 2020-04
- Volume
- 476
- Pages
- 1-12
- ISSN
- 0304-3835 (ISSN-L)
- OpenAlex
- W3005468192
- Cited by
- 746
- References
- 154
- FWCI
- 44.15
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.